CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 110 filers reported holding CUREVAC N V in Q4 2021. The put-call ratio across all filers is 1.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,524,294 | -27.4% | 516,002 | +10.8% | 0.00% | 0.0% |
| Q2 2023 | $4,853,532 | +49.9% | 465,790 | +0.2% | 0.00% | 0.0% |
| Q1 2023 | $3,238,547 | +148.9% | 464,641 | +115.3% | 0.00% | – |
| Q4 2022 | $1,301,100 | -57.3% | 215,771 | -44.2% | 0.00% | -100.0% |
| Q3 2022 | $3,049,000 | -67.3% | 386,976 | -43.5% | 0.00% | -50.0% |
| Q2 2022 | $9,326,000 | +69.1% | 685,270 | +143.7% | 0.00% | +100.0% |
| Q1 2022 | $5,515,000 | -53.1% | 281,224 | -18.0% | 0.00% | -50.0% |
| Q4 2021 | $11,760,000 | -9.0% | 342,757 | +44.9% | 0.00% | 0.0% |
| Q3 2021 | $12,921,000 | +141.2% | 236,560 | +224.5% | 0.00% | +100.0% |
| Q2 2021 | $5,356,000 | +247.1% | 72,893 | +331.9% | 0.00% | – |
| Q1 2021 | $1,543,000 | +65.6% | 16,876 | +46.9% | 0.00% | – |
| Q4 2020 | $932,000 | +189.4% | 11,491 | +66.0% | 0.00% | – |
| Q3 2020 | $322,000 | – | 6,921 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bill & Melinda Gates Foundation | 3,134,780 | $286,707,000 | 46.92% |
| Ally Bridge Group (NY) LLC | 110,000 | $10,061,000 | 1.93% |
| Parametrica Management Ltd | 44,695 | $3,968,000 | 1.91% |
| Renaissance Capital LLC | 123,983 | $11,339,000 | 1.68% |
| Samsara BioCapital, LLC | 95,318 | $8,718,000 | 1.61% |
| Ikarian Capital, LLC | 360,000 | $32,925,000 | 1.11% |
| SECTOR GAMMA AS | 25,000 | $2,287,000 | 0.42% |
| Fosun International Ltd | 50,000 | $4,438,000 | 0.35% |
| Ikarian Capital, LLC | 100,000 | $9,145,000 | 0.31% |
| Baillie Gifford | 5,830,101 | $533,221,000 | 0.30% |